DHEA and Pregnenolone on TRT: What the Research Shows and When Supplementation Makes Sense

When you start testosterone replacement therapy, exogenous testosterone tells the hypothalamus and pituitary to shut down LH and FSH production. That is expected — it is the mechanism by which TRT works. But LH does not only drive testosterone synthesis in the Leydig cells. It also stimulates the upstream steroidogenic pathway, which means the precursor hormones DHEA (dehydroepiandrosterone) and pregnenolone decline as a downstream consequence. A 2004 study in the Journal of Clinical Endocrinology & Metabolism measured DHEA-S levels in 62 men on TRT and found a mean decline of 25-40% within 12 weeks of initiating therapy. Pregnenolone, which sits even higher in the steroid cascade, tends to drop by a similar magnitude, though it is studied less frequently because most standard hormone panels do not include it. Does this decline matter? For some men, yes. DHEA and pregnenolone are not just testosterone precursors — they are neuroactive steroids with independent roles in cognitive function, mood regulation, immune modulation, and joint health. Pregnenolone in particular acts on GABA-A receptors and has been investigated in clinical trials for cognitive performance and memory. When these hormones fall to the bottom of their reference ranges or below, some men experience symptoms that TRT alone does not resolve: persistent brain fog despite good testosterone levels, flat mood, joint stiffness that seems disproportionate to activity level, or a general sense that something is still off. This article walks through the research on DHEA and pregnenolone during TRT, the clinical data on supplementation, practical dosing, monitoring, and when it is likely a waste of money. None of this is medical advice — always work with a qualified provider who can interpret your labs in context and adjust your protocol accordingly.

The adrenal steroid pathway starts with cholesterol, which gets converted to pregnenolone by the enzyme CYP11A1 (cholesterol side-chain cleavage enzyme). From pregnenolone, the pathway branches: one branch leads to progesterone, cortisol, and aldosterone. The other branch converts pregnenolone to DHEA via CYP17A1 (17-alpha-hydroxylase/17,20-lyase), and DHEA eventually converts to androstenedione and then testosterone. In a man with intact HPT axis function, LH stimulates the testes to run this entire cascade locally, producing not just testosterone but also meaningful quantities of pregnenolone, DHEA, and other intermediates. The testes account for roughly 20-30% of circulating DHEA in young men, according to data published in Endocrine Reviews. The adrenal glands produce the rest. When exogenous testosterone shuts down LH, you lose the testicular contribution entirely. The adrenal glands continue their baseline production, but they cannot compensate for the testicular loss — the adrenal output is governed by ACTH, not LH, and does not upregulate in response to lower DHEA levels. This is why some TRT clinics routinely check DHEA-S and pregnenolone at baseline and again at 8-12 weeks. If a man's adrenal production is robust, the decline may be clinically insignificant — DHEA-S stays in the mid-range and symptoms do not emerge. But if adrenal output is already compromised (chronic stress, poor sleep, aging — adrenal DHEA production declines roughly 2-3% per year after age 30 according to longitudinal data from the Baltimore Longitudinal Study of Aging), the loss of testicular contribution can push levels into the symptomatic range. There is also a less-discussed mechanism involving HCG. Men who take HCG alongside TRT to preserve fertility or testicular volume are partially maintaining LH receptor stimulation in the Leydig cells. This keeps some upstream steroidogenesis active, which is why men on TRT + HCG often maintain better DHEA and pregnenolone levels than men on TRT alone. A 2005 study by Coviello et al. demonstrated that HCG co-administration during exogenous testosterone preserved intratesticular testosterone concentrations — and by extension, the upstream pathway intermediates. If you are already on HCG and your DHEA-S levels are fine, supplementation may be unnecessary.

The research on DHEA supplementation is larger than most people expect. A meta-analysis published in 2013 in the European Journal of Endocrinology reviewed 25 randomized controlled trials of DHEA supplementation in men and women. In men, the findings were mixed: DHEA at 25-50 mg/day reliably raised DHEA-S levels into the upper-normal range, but improvements in subjective well-being, body composition, and sexual function were inconsistent across trials. The strongest signal for benefit appeared in men who started with low baseline DHEA-S — below roughly 150 mcg/dL. Men with mid-range or higher DHEA-S at baseline showed minimal improvement. A frequently cited study is the DHEAge trial (Baulieu et al., 2000, PNAS), which gave 50 mg/day DHEA to 280 men and women over age 60 for one year. Women showed clearer benefits in bone density, skin health, and libido. Men showed modest improvements in skin and some cognitive measures, but the effects were less pronounced. Critics note that the study population was not specifically men on TRT, so the findings may not translate directly. For pregnenolone, the evidence base is thinner. Most clinical trials have focused on psychiatric applications — a 2014 randomized trial in Psychopharmacology found that pregnenolone at 500 mg/day improved working memory and reduced negative symptoms in schizophrenia patients. At the doses used in TRT protocols (typically 50-100 mg/day), the research is largely observational and clinical-experience based rather than RCT-driven. What we do know: pregnenolone crosses the blood-brain barrier, modulates GABA and NMDA receptors, and has neuroprotective properties in animal models. Whether these mechanisms translate to subjective cognitive improvements at physiological replacement doses in men on TRT remains an open question. Practical dosing from TRT-specialty clinics generally looks like this: DHEA at 25-50 mg daily (taken in the morning to mimic the natural cortisol and DHEA diurnal rhythm), pregnenolone at 50-100 mg daily. Both are available over the counter in the US. Some providers start with DHEA alone and add pregnenolone only if symptoms persist or if pregnenolone levels remain low on follow-up labs. Others start both simultaneously, which makes it harder to attribute any improvement to one or the other. The monitoring side matters. DHEA converts downstream — not just toward testosterone, but also toward estrogens. Men supplementing DHEA at 50 mg/day or higher should track estradiol alongside DHEA-S to make sure they are not inadvertently driving up E2 through the aromatase pathway. This is especially relevant for men who are already managing estradiol on TRT with an aromatase inhibitor or dose adjustment. Dosed lets you log DHEA and pregnenolone doses alongside your TRT protocol and track labs over time, which makes it straightforward to spot trends when adjusting these variables.

The clearest case for supplementation is a man on TRT with documented low DHEA-S (below 150 mcg/dL or the bottom quartile of the age-adjusted reference range), low pregnenolone, and persistent symptoms that TRT has not resolved — particularly brain fog, flat affect, or joint issues that are not explained by other causes. In this scenario, a 3-month trial of DHEA 25-50 mg and/or pregnenolone 50-100 mg, with labs at baseline and follow-up, is a reasonable and low-risk intervention. The case gets weaker when DHEA-S is mid-range or higher. If your DHEA-S is 300 mcg/dL and you feel fine, adding DHEA is unlikely to improve anything and introduces unnecessary downstream conversion risk. Similarly, if you are on HCG and your upstream hormones are already maintained, supplementation is probably redundant. Age matters. A 35-year-old man on TRT whose adrenal DHEA output is still robust will experience a smaller absolute decline from losing the testicular contribution compared to a 55-year-old whose adrenal production has already dropped significantly. The older population is more likely to benefit, which is consistent with the clinical trial data showing stronger effects in older cohorts. Some men report dramatic improvements from pregnenolone specifically — the brain fog clears, they feel sharper, their mood stabilizes. Others notice nothing at all. The individual variation is large, and there is no reliable predictor of who will respond. This is why the trial-and-measure approach is the practical standard: try it for 8-12 weeks, track your symptoms and labs, and make a data-driven decision about whether to continue. A few pitfalls to avoid: do not megadose DHEA thinking more is better. Doses above 100 mg/day are associated with acne, oily skin, hair loss (via DHT conversion), and estradiol elevation without proportional additional benefit. Do not take DHEA or pregnenolone at night — both have mild stimulatory properties that can interfere with sleep. And do not assume that because these are over-the-counter supplements, they are irrelevant to your overall protocol — they feed into the same steroid pathways that your TRT provider is managing, so keep your provider informed. Tracking this in Dosed alongside your TRT, HCG, and AI doses gives you a complete picture of every variable in the protocol. When something changes — better mood, worse acne, estradiol creeping up — you can look at the timeline and see exactly what shifted and when. That is how you turn a guess into a data point.